Archived Newsletters
-
03.29.24 -- Outsourcing Nirvana At Eli Lilly
3/29/2024
03/29/24 Outsourced Pharma Newsletter
-
03.28.24 -- Optimizing CGT Development: Modular Approaches And Cryopreservation Insights
3/28/2024
03/28/24 Outsourced Pharma Newsletter
-
03.28.24 -- Developing Cell & Gene Therapies: Optimization-By-Design, Analytical Ultracentrifugation, Candidate Screening, And Feasibility Studies
3/28/2024
03/28/24 Outsourced Pharma Newsletter
-
03.28.24 -- Creating T Cell Vaccines In The Sands
3/28/2024
03/28/24 Outsourced Pharma Newsletter
-
03.27.24 -- 2024 LIMS Trends
3/27/2024
03/27/24 Outsourced Pharma Newsletter
-
03.26.24 -- Driving Efficiency And Effectiveness In Biopharmaceutical DevelopmentĀ
3/26/2024
03/26/24 Outsourced Pharma Newsletter
-
03.26.24 -- Rising API Complexity, Sustainable Production, PBPK Modeling, And Nitrosamine Reduction
3/26/2024
03/26/24 Outsourced Pharma Newsletter
-
03.26.24 -- Beyond (And Better Than) mRNA: T Cell Vaccines
3/26/2024
03/26/24 Outsourced Pharma Newsletter
-
03.25.24 -- Fast-Tracking Process Characterization, Finding Next-Gen Expression Systems, And De-Risking Development
3/25/2024
03/25/24 Outsourced Pharma Newsletter
-
03.25.24 -- Risk And Supply Chain Continuity Management: Biologics Industry Perspectives
3/25/2024
03/25/24 Outsourced Pharma Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more